Rational Design of Live Biotherapeutic Products for the Prevention of Clostridioides difficile Infection - Takeaways - MDSpire

Rational Design of Live Biotherapeutic Products for the Prevention of Clostridioides difficile Infection

  • By

  • Shanlin Ke

  • Javier A Villafuerte Gálvez

  • Zheng Sun

  • Yangchun Cao

  • Nira R Pollock

  • Xinhua Chen

  • Ciarán P Kelly

  • Yang-Yu Liu

  • September 24, 2024

  • 0 min

Share

  • 1

    Clostridioides difficile infection (CDI) is a leading cause of healthcare-associated diarrhea, affecting 500,000 patients annually in the US.

  • 2

    Fecal microbiota transplantation (FMT) is effective for recurrent CDI but has unknown mechanisms and potential pathogen transmission risks.

  • 3

    Live biotherapeutic products (LBPs) using predefined bacterial consortia offer a promising alternative to FMT for preventing CDI.

  • 4

    A computational framework was developed to identify microbial strains for LBPs targeting CDI, resulting in a catalog of 3741 nonredundant metagenome-assembled genomes.

  • 5

    The study highlights the importance of strain-level analysis in understanding the human microbiome's role in health and disease.

Original Source(s)

Rational Design of Live Biotherapeutic Products for the Prevention of Clostridioides difficile Infection

  • by Shanlin Ke, Javier A Villafuerte Gálvez, Zheng Sun, Yangchun Cao, Nira R Pollock, Xinhua Chen, Ciarán P Kelly, Yang-Yu Liu

  • September 24, 2024

Related Content

Not All Lung Bacteria Are the Enemy

Cross-disease meta-analysis also found modest associations with lung function, though findings varied by disease type

Antibiotic Falls Short in Disc-Related Back Pain

A randomized trial found no greater pain reduction vs placebo, but questions remain about patients with type 1 Modic changes.

Colonizing Corneal Healing

Genetically engineered ocular bacteria accelerates corneal wound healing by colonizing the eye and secreting interleukin-10

  • April 17, 2026

  • 3 min